Am J Prev Med by Park, Chanhyun et al.
Cost-effectiveness Analyses of Antihypertensive Medicines: A 
Systematic Review
Chanhyun Park, PhD, MPharm, MEd, Guijing Wang, PhD, Jefferey M. Durthaler, MS, 
BS(Pharm), and Jing Fang, MD, MS
Division for Heart Disease and Stroke Prevention, US Centers for Disease Control and 
Prevention, Atlanta, Georgia
Abstract
Context—Hypertension affects one third of the U.S. adult population. Although cost-
effectiveness analyses of antihypertensive medicines have been published, a comprehensive 
systematic review across medicine classes is not available.
Evidence acquisition—PubMed, Embase, Cochrane Library, and Health Technology 
Assessment were searched to identify original cost-effectiveness analyses published from 1990 
through August 2016. Results were summarized by medicine class: angiotensin-converting 
enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers 
(CCBs), thiazide-type diuretics, β-blockers, and others. Incremental cost-effectiveness ratios 
(ICERs) were adjusted to 2015 U.S. dollars.
Evidence synthesis—Among 76 studies reviewed, 14 compared medicines with no treatment, 
16 compared medicines with conventional therapy, 29 compared between medicine classes, 13 
compared within medicine class, and 11 compared combination therapies. All antihypertensives 
were cost effective compared with no treatment (ICER/quality-adjusted life year 
[QALY]=dominant–$19,945). ARBs were more cost effective than CCBs (ICER/
QALY=dominant–$13,016) in nine comparisons, whereas CCBs were more cost effective than 
ARBs (ICER/QALY=dominant) in two comparisons. ARBs were more cost effective than ACEIs 
(ICER/QALY=dominant–$34,244) and β-blockers (ICER/QALY=$1,498–$18,137) in all eight 
comparisons.
Conclusions—All antihypertensives were cost effective compared with no treatment. ARBs 
appeared to be more cost effective than CCBs, ACEIs, and β-blockers. However, these latter 
findings should be interpreted with caution because these findings are not robust due to the 
substantial variability across the studies, including study settings and analytic models, changes in 
the cost of generic medicines, and publication bias.
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CONTEXT
Hypertension is associated with a high economic burden at the individual and population 
levels. It is one of the most common primary diagnoses in the U.S., affecting one third of the 
adult population.1 In the U.S., the annual estimated direct and indirect costs of hypertension 
were $47.3 billion and $3.9 billion, respectively (annual average 2012–2013).2 The annual 
costs for patients treated for hypertension averaged $733 per adult in 2010.3 In addition, 
hypertension is an independent risk factor for other costly diseases. Antihypertensive 
therapy reduces the incidence of stroke (35%–40%), myocardial infarction (20%–25%), and 
heart failure (>50%).4 Prescription medicine costs account for about half of the total medical 
costs for the treatment of hypertension.3,5,6
Many pharmacologic treatment options are available for the management of hypertension. 
The following medicine classes are commonly used7: Angiotensin-converting enzyme 
inhibitors (ACEIs) inhibit the formation of angiotensin II, which is a vasoconstrictor. 
Angiotensin II receptor blockers (ARBs) block the binding of angiotensin II to receptors on 
blood vessels, leading to vasodilation. Calcium channel blockers (CCBs) decrease vascular 
resistance by vascular smooth muscle relaxation. Diuretics are divided into three groups: 
thiazide-type or thiazide-like diuretics (TDs), loop diuretics, and potassium-sparing 
diuretics. TDs are the most commonly used diuretics,8 and work by blocking sodium 
chloride reabsorption at the distal convoluted tubule cells in the kidneys. β-blockers inhibit 
activation by directly suppressing renin release and also block the effects of circulating 
catecholamines and reduce heart rate and cardiac output.
The 2014 evidence-based guideline for the management of high blood pressure in adults9 
recommends several possible medicine classes for initial treatment of hypertension. TD, 
CCB, ACEI, or ARB classes are recommended as the initial choice of antihypertensive 
medicines for non–African-American patients and for patients with diabetes. For African-
American patients TDs and CCBs are recommended, and for patients with chronic kidney 
disease, ACEIs and ARBs are recommended. Prescribers may consider adding another 
medicine from TD, CCB, ACEI, or ARB classes for the second step, and then β-blockers, 
aldosterone antagonists, or others for the third step. Similarly, several medicine classes are 
recommended for first-line therapy in the National Institute for Health and Care Excellence 
guideline for hypertension.10 The recommended initial treatment option is ACEIs or low-
cost ARBs for patients aged <55 years, CCBs for those aged ≥55 years or African American, 
and TD if CCBs are not suitable; β-blockers are not a preferred initial therapy. The second-
line therapy is dual therapy of ACEs or ARBs with a CCB for most patients. The third-line 
therapy is the use of three medicines, including ACE or ARB with a CCB, and a TD, if 
required. Because several pharmacologic treatment options can be used for the first-line 
therapy, it is important to evaluate which medicines are more cost effective among those 
options.
The evidence from pharmacoeconomic evaluations can provide valuable information for 
decision makers in setting public health priorities. Many pharmacoeconomic studies of 
antihypertensive medicines conducted in recent years have found control of hypertension to 
be cost effective. Several systematic reviews of these studies also have been published, but 
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their focus has been on a specific medicine, such as irbesartan,11 or medicine class, such as 
ACEIs or ARBs.12 Thus, no comprehensive review has been conducted for studies across all 
anti-hypertensive medicine classes. The objectives are to systematically review all 
pharmacoeconomic evaluations of antihypertensive medicines and summarize the cost 
effectiveness of these medicines.
EVIDENCE ACQUISITION
Search Strategy
A systematic review was conducted following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines.13 The authors performed a literature 
search using PubMed, Embase, Cochrane Library, and Health Technology Assessment from 
January 1, 1990 through August 31, 2016. The search terms were a combination of study 
type (health economics OR pharmacoeconomics OR economic burden OR cost analysis OR 
economic analysis OR cost-effectiveness OR cost-utility OR cost-benefit) and study 
intervention or outcomes (hypertension OR high blood pressure OR antihypertensive). All 
references were manually checked for the review articles retrieved.
Eligibility Criteria
Pharmacoeconomic studies were included if: (1) the study population was being treated for 
hypertension; (2) antihypertensive medicines were used to treat hypertension; (3) both costs 
and outcomes were assessed; (4) outcomes were reported as natural unit (e.g., life year [LY], 
blood pressure reduction, cardiovascular event avoided), utility unit (quality-adjusted life 
year [QALY]), or monetary unit; and (5) full-text articles were published in English. Studies 
were excluded if they did not describe specific antihypertensive medicines and compared 
medicine adherence, medicine price, single-pill fixed-dose combination therapy, and 
administration times.
Data Extraction
Studies that met eligibility criteria were categorized by five comparison types: (1) medicines 
versus placebo or no treatment; (2) medicines versus conventional therapy or standard of 
care that was defined as a situation where patients used any medicines that they had used 
before clinical trials except intervention medicines, but authors did not describe the names of 
medicines; (3) medicines between different medicine classes; (4) medicines within the same 
medicine class; and (5) different combination therapies. The cost-effectiveness evidence of 
medicines was summarized by medicine class: ACEIs, ARBs, CCBs, TDs, β-blockers, and 
others. The following information was summarized for each study: country where the study 
was conducted, medical conditions of study population, kind of economic evaluation 
methods, perspective, study framework, time horizon, sensitivity analyses, treatment type, 
outcomes, funding source, and cost-effectiveness evidence (e.g., incremental cost-
effectiveness ratio [ICER]). Two reviewers screened studies according to the eligibility 
criteria, and differences were resolved by consensus between the reviewers. The cost 
estimates of the studies were adjusted to 2015 U.S. dollars using the Personal Consumption 
Expenditures by Health Function.14 For studies reporting costs in other currencies, the 
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Purchasing Power Parity Index was used to convert the estimates to U.S. dollars in the same 
year and then adjusted for inflation.15
Quality Assessment
The quality of the pharmacoeconomic studies was assessed by the 100-point Quality of 
Health Economic Studies scale with all 16 items.16
EVIDENCE SYNTHESIS
Study Characteristics
Figure 1 is a flow diagram of the review process based on the PRISMA guideline. A total of 
3,247 potentially relevant articles were identified. After excluding duplication, the abstracts 
of 2,718 articles were screened and 1,885 were excluded. Then the full text of 833 articles 
was screened to assess eligibility based on the inclusion criteria. Through this process, 99 
articles were identified as pharmacoeconomic studies of antihypertensive medicines. An 
additional 23 studies were excluded for not meeting the inclusion criteria, and the remaining 
76 studies were grouped into (1) studies that compared antihypertensive medicines with no 
treatment (n=14), (2) studies that compared antihypertensive medicines with conventional 
therapy (n=16), (3) studies that compared medicines between medicine classes (n=28), (4) 
studies that compared medicines within medicine class (n=13), and (5) studies that 
compared different combination therapies (n=11). Six studies were included in two groups.
Table 1 shows the characteristics of pharmacoeconomic studies of antihypertensive 
medicines. Most studies were conducted in Europe (n=41), followed by North America 
(n=16). About half of the study populations were patients with hypertension alone (n=39), 
and another half were patients with hypertension and comorbidities (n=37). Cost-
effectiveness analysis and cost-utility analysis were used frequently (n=56 and n=31, 
respectively). The perspectives of health care and third-party payer were used frequently. 
Among 64 studies that reported funding source for research, 80% (n=51) received partial or 
full support from private industry.
Figure 2 shows the frequencies of antihypertensive medicines analyzed in the literature. 
Thirty-six medicines were assessed. ARBs were the most frequently evaluated and were 
assessed 62 times as either interventions or comparators in 42 studies. The most frequently 
included ARBs were losartan (n=20) and irbesartan (n=15). CCBs were assessed 32 times 
(n=31) and amlodipine was the most commonly used medicine in this class (n=19). Cost 
effectiveness of ACEIs was assessed 28 times (n=28). β-blockers were included 25 times 
(n=23) and atenolol was the most common medicine in this class (n=16). Cost effectiveness 
of TDs was evaluated 17 times (n=17) and hydrochlorothiazide (HCTZ) was the most 
frequently used medicine in this class (n=10). The mean Quality of Health Economic 
Studies score was 82.5 points (SD=13.8 points). Appendix Table 1 (available online) 
describes the results of quality assessment in the literature based on the Quality of Health 
Economic Studies instrument.
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Cost-Effectiveness Evidence
Table 2A shows the summary of cost effectiveness of antihypertensive medicines compared 
with no treatment and conventional treatment. In 14 studies, all types of medicines were cost 
effective compared with placebo/no treatment (25 comparisons). Of these 14 studies, 
hypertension was defined by systolic blood pressure in five studies: ≥160 mmHg for two 
studies, ≥150 mmHg for one study, and ≥140 mmHg for two studies. ACEIs and TDs were 
frequently evaluated medicines (ten comparisons for both) and ARBs and β-blockers were 
also assessed (four comparisons and one comparison, respectively). The ICER ranges were 
from dominant to $19,945 for QALY and from dominant to $13,856 for LY. The least cost-
effective scenario for QALY was the mono-therapy of HCTZ, and that for LY was the 
combination therapy of perindopril and indapamide. Appendix Table 2 (available online) 
summarizes each article on the comparisons between antihypertensive medicines and no 
treatment.
For 16 studies, the control group was treated with conventional therapy, which was mostly 
defined as using control hypertensive medicines (e.g., β-blockers, TDs, and other classes) 
except intervention hypertensive medicines (e.g., ACEIs, ARBs, and CCBs) without the 
specification of medicine name. All types of medicines were more cost effective than 
conventional treatment (16 comparisons), except one comparison that amlodipine was less 
cost effective. The most frequent evaluations were ARBs (13 comparisons) and ACEIs and 
CCBs were also assessed (two comparisons for each). Except for amlodipine, the ICER 
ranged from dominant to $29,331 for QALY, and the least cost-effective scenario for QALY 
was the use of irbesartan. Intervention medicines were a dominant option for LY compared 
with conventional treatment. Appendix Table 3 (available online) provides the summary of 
each article on the comparisons between intervention antihypertensive medicines and 
conventional treatment used in this review.
Table 2B summarizes the cost effectiveness of antihypertensive medicines from different 
medicine classes. The cost effectiveness of ARBs was most frequently assessed. First, nine 
of 11 comparisons between ARBs and CCBs concluded that ARBs were more cost effective 
than CCBs. Eprosartan, irbesartan, losartan, and valsartan were cost effective compared with 
amlodipine, and eprosartan was cost effective compared with nitrendipine (ICER/
QALY=dominant–$10,016, ICER/LY=dominant); whereas CCBs (amlodipine) were more 
cost effective than ARBs (valsartan) in two comparisons. Second, all studies concluded that 
ARBs were more cost effective than ACEIs and β-blockers. Regarding ACEIs, eprosartan 
was more cost effective than enalapril and perindopril, and losartan was more cost effective 
than fosinopril (three comparisons; ICER/QALY=dominant–$34,244, ICER/LY=dominant). 
Regarding β-blockers, losartan was more cost effective than atenolol (five comparisons; 
ICER/QALY=$1,498–$18,137, ICER/LY=dominant–$13,603). Third, only one comparison 
between ARBs and TDs was evaluated, which found that chlorthalidone was more cost 
effective than losartan (ICER not reported).
In three comparisons between CCBs and ACEIs, CCBs were the more cost-effective option. 
Nifedipine was more cost effective than lisinopril or captopril, and amlodipine was more 
cost effective than enalapril (ICER not reported). When comparing CCBs with β-blockers, 
the results were inconsistent. Nifedipine was more cost effective than propranolol in one 
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comparison (ICER not reported), whereas propranolol was more cost effective than 
nifedipine in one comparison (ICER not reported). In the comparison between CCBs and 
TDs, amlodipine was more cost effective than chlorthalidone (one comparison; ICER/
QALY=$53,594, ICER/LY=$62,202), whereas HCTZ and chlorthalidone were more cost 
effective than nifedipine and amlodipine (two comparisons; ICER not reported). TDs were 
more cost effective than ACEIs in five comparisons (ICER/QALY=dominant, ICER/
LY=dominant, HCTZ vs lisinoril, enalapril, or captopril, and chlorthalidone vs lisinoril and 
enalapril), whereas ACEIs were more cost effective than TDs in only one study (ICER/
QALY=$19,474, enalapril vs HCTZ).
ARBs were more cost effective than CCBs in hypertensive patients with diabetes or renal 
disease, or both, in all comparisons. Specifically, irbesartan and valsartan were more cost 
effective than amlodipine in patients with diabetes mellitus (five comparisons and one 
comparison, respectively; ICER/QALY=dominant, ICER/LY=dominant) and renal disease 
(six comparisons; ICER/QALY=dominant, ICER/LY=dominant). ARBs were more cost 
effective than β-blockers in hypertensive patients with left ventricular hypertrophy in all 
comparisons. Specifically, losartan was more cost effective than atenolol (four comparisons; 
ICER/QALY=$1,498–$18,137, ICER/LY=dominant–$13,603). Appendix Table 4 (available 
online) summarizes the articles on the comparisons of antihypertensive medicines between 
different medicine classes.
Table 2C summarizes 13 studies about the cost effectiveness of antihypertensive medicines 
within the same medicine class for ARBs, β-blockers, and CCBs. ARBs were the most 
frequently evaluated class; ten studies made 19 comparisons. Overall, olmesartan, irbesartan, 
candesartan, and telmisartan were more cost effective than losartan and valsartan. 
Olmesartan, irbesartan, candesartan, telmisartan, and valsartan were more cost effective than 
losartan (eight comparisons; ICER/QALY=dominant–$33,567, ICER/LY=dominant–
$28,326), whereas losartan was more cost effective than candesartan in one comparison. 
Olmesartan, irbesartan, candesartan, and telmisartan were more cost effective than valsartan 
(six comparisons; ICER/QALY=dominant–$34,678, ICER/LY=$10,275–$27,006). 
Appendix Table 5 (available online) provides the summary of each study on the comparisons 
of antihypertensive medicines within the medicine classes.
Eleven studies compared the cost effectiveness of different types of combination therapies. 
In two studies, amlodipine-based treatment with perindopril as an adjunct treatment was 
more cost effective than atenolol-based treatment with bendroflumethiazide as an adjunct 
treatment (ICER/QALY=$5,649–$31,975, ICER/LY=$20,495–$31,165). Dual therapies 
were more cost effective than monotherapy and triple therapy. A dual therapy of azelnidipine 
and olmesartan was more cost effective than a monotherapy with either azelnidipine or 
olmesartan (ICER/QALY=dominant). A dual therapy of candesartan (low dose) and 
nifedipine was also more cost effective than a monotherapy with candesartan or nifedipine 
(ICER/blood pressure reduction=dominant). However, a triple therapy of bendrofluazide, 
atenolol, and enalapril was less cost effective than a dual therapy of bendrofluazide and 
atenolol (ICER=not reported). Appendix Table 6 (available online) summarizes the articles 
on the comparisons among different types of combination therapies.
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DISCUSSION
Cost-Effectiveness Evidence
As expected, this review found that treating hypertension with medicines was consistently 
more cost effective than not treating it, thanks to the remarkable progress in the treatment of 
hypertension in recent decades. ARBs were found to be more cost effective than CCBs in 
nine comparisons, whereas CCBs appeared to be more cost effective than ARBs in two 
comparisons. ARBs were more cost effective than ACEIs and β-blockers in all eight 
comparisons. Within ARBs, losartan was a less cost effective medicine in eight comparisons. 
These findings are less robust because of the heterogeneity of study setting and analytic 
methods and changes in the cost of generic medications.
A previous study found that approximately one half of U.S. adults with hypertension did not 
have their hypertension controlled. Of those who were uncontrolled: 33.1% were unaware; 
20.3% were aware, but uncontrolled; and 46.6% were aware, treated, and uncontrolled.17 
When considering the economic benefit of treating hypertension, more effort should be 
required to identify people who are not aware of their hypertension and to treat those who 
are not receiving treatment despite being aware of their hypertension.
Pharmacoeconomic evaluations of medicines are usually conducted for newly marketed 
medicines. ARBs are the newest class of antihypertensive medicine. In 1995, the first ARB, 
losartan, was approved by the U.S. Food and Drug Administration, followed by valsartan in 
1996. Irbesartan, eprosartan, candesartan, telmisartan, and olmesartan were approved 
between 1997 and 2002.18 Thus, ARBs were the most frequently evaluated—in 42 of 76 
studies in this review, mostly published between 2000 and 2009. The studies reviewed found 
that ARBs were a more cost-effective option than medicines in the CCB, ACEI, or β-blocker 
classes. Furthermore, losartan and valsartan, the first U.S. Food and Drug Administration –
approved ARBs, were less favorable options among ARBs. Thus, more frequent evaluations 
of ARBs may lead to better cost-effectiveness results for this medicine class, especially for 
more recently marketed ARBs than losartan and valsartan.
This review found that ARBs were more cost effective than CCBs in hypertensive patients 
with diabetes and renal disease (irbesartan and valsartan versus amlodipine) and β-blockers 
in patients with left ventricular hypertrophy (losartan versus atenolol). According to the new 
evidence-based guideline for the management of high blood pressure,9 TDs, CCBs, ACEIs, 
and ARBs are recommended as the initial choice for patients with diabetes, and ACEIs and 
ARBs are recommended for patients with chronic kidney disease. The findings of this 
review could be useful for choosing appropriate anti-hypertensive medicines for patients 
with diabetes, renal disease, or left ventricular hypertrophy.
Study Design and Quality
When assessing study quality, study perspective, the source of input parameters, time 
horizons, and outcome measures must be considered. Societal perspective is the gold 
standard of pharmacoeconomic studies because it incorporates all costs and health 
outcomes, although other perspectives may be better for some decision-making situations.
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19,20
 However, only a few studies in this review used a societal perspective. The majority 
stated that they considered a payer perspective (e.g., third-party payer perspective).
Second, efficacy refers to outcomes under ideal circumstances, whereas effectiveness refers 
to outcomes under real-world settings.21,22 Although efficacy and effectiveness lie on a 
continuum, the source of input parameters of pharmacoeconomic studies from clinical trials 
have higher internal validity, whereas those from observation studies have higher external 
validity. About one third of the studies combined efficacy data from clinical trials using a 
Markov model, and another third evaluated efficacy data from clinical trials by using 
regression-type analyses. Thus, the source of input parameters came from clinical trials in 
the majority of the included studies.
Third, more than half of the studies adopted a time horizon of less than 10 years, even 
though hypertension is a chronic disease. Although medicine dosages might be able to be 
reduced after patients achieve normal blood pressure and maximize healthy lifestyle 
behaviors beneficial for hypertension control (maintaining a normal weight, being physically 
active, and consuming a low sodium diet) and maintain it for a year or more, the use of 
antihypertensive medicines is often not able to be stopped. Treatment frequently should be 
continued over a lifetime.23 When considering the natural course of hypertension, a long 
time horizon is preferred for pharmacoeconomic studies.
Finally, a number of outcomes were evaluated in the studies. Primary clinical outcomes were 
commonly used. The most common outcome was LYs, followed by QALYs. Other 
intermediate clinical outcomes were blood pressure reduction and avoiding cardiovascular 
disease events, end-stage renal disease, or dialysis. QALYs has been considered a more 
important measure of effectiveness in pharmacoeconomic evaluation than LYs.24,25 
However, only about 40% of the included studies used QALYs as an effectiveness measure 
in this review.
This study has several strengths. First, this review is the first comprehensive synthesis of the 
evidence of cost effectiveness for antihypertensive medicines to the authors’ knowledge, and 
it presents detailed cost-effectiveness information. Second, this review included the majority 
of the published cost-effectiveness studies of antihypertensive medicines and adjusted all 
cost-related values from different time and settings to 2015 U.S. dollars for better 
comparison. Finally, this review also assessed quality of the literature and pointed out the 
weaknesses of the literature. Because the findings from the literature were similar across 
low- and high-quality literature, this review included all 76 studies. In addition, identifying 
the weaknesses of the current literature will help future cost-effectiveness analyses of 
antihypertensive medicines.
Limitations
This study also has several limitations. First, only English language peer-reviewed 
publications were included. Thus, other important pharmacoeconomic studies of 
antihypertensive medicines published in non-English language peer-reviewed journals may 
have been missed. Second, the availability of generic medicines changes over time. 
Although it is well known that substituting generic medicines for brand-name medicines 
Park et al. Page 8
Am J Prev Med. Author manuscript; available in PMC 2018 March 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
lowers costs,26 it is important to acknowledge the impact of including pharmacoeconomic 
studies that do not specify the cost—based on generic or brand formulations or both —on a 
cost-effectiveness analysis. For example, since losartan became available as a generic in 
2010,27 the results of studies evaluating the cost effectiveness of losartan prior to 2010 
cannot be generalized with the results of studies conducted after 2010. The same is true for 
all other ARBs cost-effectiveness studies where the cost of the formulation (i.e., generic 
versus brand) was not specified. In this analysis, most studies did not clarify if the cost of 
medicines were based on the brand or generic formulation. For this reason, the cost-
effectiveness calculations reported in this report may be imperfect, and the usefulness of the 
results limited. Finally, cost-effectiveness evidence may depend on the blood pressure level, 
race/ethnicity, age, or comorbidity status of the patients. However, many studies in the 
literature did not provide this specific information; thus, cost-effectiveness evidence for 
specific population groups could not be derived.
These findings should be interpreted with caution for several reasons. First, potential 
conflicts of interest for authors of industry-sponsored studies may have influenced the way 
they develop models and gathered input information for analytic models. A systematic 
review on bias in published cost-effectiveness studies demonstrated that studies sponsored 
by industry were associated with a favorable cost-effectiveness ratio compared with studies 
sponsored by non-industry sources, although there was no difference in the quality of the 
research.28,29 In this review, 64 studies reported a funding source for research, 51 (80%) of 
them financially supported by industry. These studies provided positive evidence for the 
companies that sponsored them. As such, there is a possibility of publication bias of the 
results in this review. Another reason is a substantial variability across studies. For example, 
study settings varied across countries because of differences in financial and healthcare 
systems,30,31 and drug prices often differ widely because of bargaining power.32 Many 
studies were conducted in Europe. This may be due to the fact that European governments 
often emphasize cost-effectiveness evidence in their healthcare system. In addition, the 
definitions and measurements of outcomes and analytical approaches in each study also 
varied across study settings and methodologies. Although studies were categorized into five 
groups, there were still substantial variabilities across studies within groups. As such, the 
Appendix Tables 1–6 (available online) are provided to summarize each study. Finally, 
although cost effectiveness of antihypertensive medicines could be an aid for clinical 
decisions, the availability of generic medicines might make the published cost-effectiveness 
information less valid.
Several research gaps were identified in the literature. First, no study assessed the cost 
effectiveness of medicines according to race/ethnicity in the U.S. Because race/ethnicity is a 
key factor when determining appropriate treatment options, future studies could evaluate the 
cost effectiveness of antihypertensive medicines by race/ethnicity. Second, more research is 
needed on the cost effectiveness of antihypertensive medicines by patient blood pressure 
level, because using hypertensive medicines may be less cost effective in patients with mild 
hypertension compared with moderate or severe hypertension. Third, more evaluations 
should be conducted on different types of combination therapies. This review found 11 
studies that compared different types of combination therapies. However, considering many 
hypertensive adults take multiple medications concurrently, research should be conducted to 
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identify optimal number of medications or types of combination by their characteristics. 
Finally, developing a standard to measure effectiveness in hypertension should be 
considered, especially in adults with other comorbidities, such as diabetes and renal disease.
CONCLUSIONS
The treatment of hypertension using antihypertensive medicines is cost effective compared 
with no treatment. Among medicine classes, ARBs appear to be more cost effective than 
CCB, ACEI, and β-blocker classes. However, these results should be interpreted with 
caution because of potential publication bias (i.e., funding bias) and the heterogeneity of 
study setting.
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Acknowledgments
Publication of this article was supported by the U.S. Centers for Disease Control and Prevention (CDC), an Agency 
of the U.S. Department of Health and Human Services, and the Association for Prevention Teaching and Research 
(APTR) Cooperative Agreement No. 1U36 OE000005.
The findings and conclusions in this publication are those of the authors and do not necessarily represent the official 
position of the CDC.
No financial disclosures were reported by the authors of this paper.
References
1. CDC. Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 
and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011; 60(4):103–108. [PubMed: 21293325] 
2. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics–2017 update: a report 
from the American Heart Association. Circulation. 2017; 135(10):e146–e603. https://doi.org/
10.1161/CIR.0000000000000485. [PubMed: 28122885] 
3. Davis, K. Expenditures for Hypertension among Adults Age 18 and Older, 2010: Estimates for the 
U.S. Civilian Noninstitutionalized Population. Statistical Brief #404. Rockville, MD: Agency for 
Healthcare Research and Quality; Apr. 2013 
4. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists’ Collaboration. 
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of 
prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment 
Trialists’ Collaboration. Lancet. 2000; 356(9246):1955–1964. https://doi.org/10.1016/
S0140-6736(00)03307-9. [PubMed: 11130523] 
5. Balu S, Thomas J 3rd. Incremental expenditure of treating hypertension in the United States. Am J 
Hypertens. 2006; 19(8):810–816. https://doi.org/10.1016/j.amjhyper.2005.12.013. [PubMed: 
16876679] 
6. Trogdon JG, Finkelstein EA, Nwaise IA, Tangka FK, Orenstein D. The economic burden of chronic 
cardiovascular disease for major insurers. Health Promot Pract. 2007; 8(3):234–242. https://doi.org/
10.1177/1524839907303794. [PubMed: 17606951] 
7. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: an update. Diabetol Metab 
Syndr. 2010; 2(1):44. https://doi.org/10.1186/1758-5996-2-44. [PubMed: 20576135] 
8. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting 
their interchangeability. Hypertension. 2004; 43(1):4–9. https://doi.org/10.1161/01.HYP.
0000103632.19915.0E. [PubMed: 14638621] 
Park et al. Page 10
Am J Prev Med. Author manuscript; available in PMC 2018 March 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
9. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high 
blood pressure in adults: report from the panel members appointed to the Eighth Joint National 
Committee (JNC 8). JAMA. 2014; 311(5):507–520. https://doi.org/10.1001/jama.2013.284427. 
[PubMed: 24352797] 
10. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Guideline Development Group. 
Management of hypertension: summary of NICE guidance. BMJ. 2011; 343:d4891. https://doi.org/
10.1136/bmj.d4891. [PubMed: 21868454] 
11. Gialama F, Maniadakis N. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of 
irbesartan. Vasc Health Risk Manag. 2013; 9:575–592. https://doi.org/10.2147/VHRM.S50831. 
[PubMed: 24124375] 
12. Huang Y, Zhou Q, Haaijer-Ruskamp FM, Postma MJ. Economic evaluations of angiotensin-
converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: 
a systematic review. BMC Nephrol. 2014; 15:15. https://doi.org/10.1186/1471-2369-15-15. 
[PubMed: 24428868] 
13. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336–341. 
https://doi.org/10.1016/j.ijsu.2010.02.007. [PubMed: 20171303] 
14. U.S. Bureau of Economic Analysis (BEA). [Accessed February 20, 2017] National Data. Table 
2.5.5. Personal Consumption Expenditures by Function. Aug 3. 2016 www.bea.gov/iTable/
iTable.cfm?reqid=9&step=1&acrdn=2#reqid=9&step=3&isuri=1&903=74
15. Organisation for Economic Co-operation and Development (OECD). [Accessed February 20, 
2017] OECD data. Purchasing power parities (PPP). https://data.oecd.org/conversion/purchasing-
power-parities-ppp.htm#indicator-chart
16. Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic 
analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003; 9(1):53–61. https://
doi.org/10.18553/jmcp.2003.9.1.53. [PubMed: 14613362] 
17. Merai R, Siegel C, Rakotz M, et al. CDC grand rounds: a public health approach to detect and 
control hypertension. MMWR Morb Mortal Wkly Rep. 2016; 65:1261–1264. https://doi.org/
10.15585/mmwr.mm6545a3. [PubMed: 27855138] 
18. Sanders, G., Coeytaux, R., Dolor, R., et al. Angiotensin-converting Enzyme Inhibitors (ACEIs), 
Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential 
Hypertension: An Update. Comparative Effectiveness Review No. 34. AHRQ Publication No. 11-
EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2011. 
www.ncbi.nlm.nih.gov/books/NBK61789/
19. Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J 
Technol Assess Health Care. 1990; 6(1):93–103. https://doi.org/10.1017/S0266462300008953. 
[PubMed: 2113893] 
20. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, 
and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and 
medicine. JAMA. 2016; 316(10):1093–1103. https://doi.org/10.1001/jama.2016.12195. [PubMed: 
27623463] 
21. Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the 
struggle between external and internal validity. BMC Med Res Methodol. 2003; 3:28. https://
doi.org/10.1186/1471-2288-3-28. [PubMed: 14690550] 
22. Gartlehner, G., Hansen, RA., Nissman, D., Lohr, KN., Carey, TS. Criteria for Distinguishing 
Effectiveness from Efficacy Trials in Systematic Reviews. Rockville, MD: Agency for Healthcare 
Research and Quality; 2006. 
23. American Heart Association. [Accessed January 24, 2017] Managing high blood pressure 
medications. www.heart.org/HEARTORG/Conditions/HighBloodPressure/
MakeChangesThatMatter/Managing-High-Blood-Pressure-
Medications_UCM_303246_Article.jsp#.WUKV701dBZs. Published 2016
24. Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R. Use of quality-
adjusted life years for the estimation of effectiveness of health care: a systematic literature review. 
Int J Technol Assess Health Care. 2006; 22(2):235–241. https://doi.org/10.1017/
S0266462306051051. [PubMed: 16571199] 
Park et al. Page 11
Am J Prev Med. Author manuscript; available in PMC 2018 March 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
25. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med 
Bull. 2010; 96:5–21. https://doi.org/10.1093/bmb/ldq033. [PubMed: 21037243] 
26. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic 
drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med. 
2005; 142(11):891–897. https://doi.org/10.7326/0003-4819-142-11-200506070-00006. [PubMed: 
15941695] 
27. U.S. Food and Drug Administration. [Accessed January 24, 2017] Generic drug roundup. Dec. 
2010 www.fda.gov/ForConsumers/ConsumerUpdates/ucm236544.htm#LosartanPotassiumTablets. 
Published 2010
28. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. 
BMJ. 2006; 332(7543):699–703. https://doi.org/10.1136/bmj.38737.607558.80. [PubMed: 
16495332] 
29. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research 
outcome and quality: systematic review. BMJ. 2003; 326(7400):1167–1170. https://doi.org/
10.1136/bmj.326.7400.1167. [PubMed: 12775614] 
30. Frogner BK, Frech HE 3rd, Parente ST. Comparing efficiency of health systems across 
industrialized countries: a panel analysis. BMC Health Serv Res. 2015; 15:415. https://doi.org/
10.1186/s12913-015-1084-9. [PubMed: 26407626] 
31. Keynejad R, Semrau M, Toynbee M, et al. Building the capacity of policy-makers and planners to 
strengthen mental health systems in low- and middle-income countries: a systematic review. BMC 
Health Serv Res. 2016; 16(1):601. https://doi.org/10.1186/s12913-016-1853-0. [PubMed: 
27769270] 
32. Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. Health 
Aff (Millwood). 2008; 27(1):221–233. https://doi.org/10.1377/hlthaff.27.1.221. [PubMed: 
18180499] 
Park et al. Page 12
Am J Prev Med. Author manuscript; available in PMC 2018 March 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Article identification and selection process of CEAs of antihypertensive medicines published 
in 1990–2016.
Note: The sum of the number of articles in the five groups was > 76 because six studies were 
included in multiple groups.
CEA, cost-effectiveness analysis; CVD, cardiovascular disease.
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Figure 2. 
Frequencies of antihypertensive medicines by medicine classes in cost-effectiveness 
analyses published in 1990–2016 (n=76).
Note: Medicines were excluded for counting if they were used as adjunctive therapy for both 
intervention and control groups or as needed. All calcium channel blockers were 
dihydropyridine calcium channel blockers. All β-blockers were β1-selective β-blockers 
except propranolol, which is non-selective.
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Table 1
Characteristics and Quality of Cost-Effectiveness Analyses of Antihypertensive Medicines Published in 1990–
2016 (n=76)
Characteristics Number of studies
Location
 Europe 41
 North America (U.S. and Canada) 16
 Others 19
Medical conditions of study population
 HTN 39
 HTN+diabetes+renal disease 12
 HTN+diabetes 9
 HTN+renal failure 4
 HTN+cardiovascular disease 9
 HTN+cerebrovascular disease 3
Economic evaluation type
 Cost-minimization analysis 1
 Cost-effectiveness analysis 42
 Cost-utility analysis 17
 Cost-benefit analysis 2
 Cost-effectiveness and utility analysis 14
Perspectivea
 Health care 30
 Third-party payer 19
 Not specified payer 8
 Societal 7
 Others 4
 Not reported 10
Study framework
 Trial-based 28
 Model-based 24
 Trial- and model-based 24
Time horizonb
 ≤1 year 13
 >1 year and ≤10 years 38
 >10 years 35
 Not reported 3
Sensitivity analysis
 Conducted 64
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Characteristics Number of studies
 Not conducted 12
Treatment type
 Monotherapy 35
 Combination therapy 14
 Monotherapy and/or combination therapy 27
Outcomesc
 QALY 31
 LY 37
 Blood pressure reduction 8
 Cardiovascular disease-related 4
 Renal disease-related 7
 Monetary 2
 Others 6
Funding source
 Private industry 46
 Nonprofit organization 8
 Private industry+nonprofit organization 5
 None 5
 Not reported 12
Quality assessment scored
 >90 21
 81–90 33
 71–80 12
 ≤70 10
a
Two studies took two perspectives.
b
Eleven studies used more than two time horizons.
cSeventeen studies assessed more than two outcomes.
d
The mean Quality of Health Economic Studies score was 82.5 (SD=13.8).
HTN, hypertension; LY, life year; QALY, quality-adjusted life year.
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Table 2A
Summary of Cost Effectiveness of Antihypertensive Medicines From the Literature Published in 1990–2016: 
Intervention Treatment Versus No Treatment and Intervention Treatment Versus Conventional Treatment 
(n=30)
Interventions
Controls
No treatment Conventional treatment
ARB preferred
 Comparison, n 4 13
 ICER QALY: dominant–$10,976
LY: $7,594
QALY: dominant–$29,331
LY: dominant
 Medicines assessed Valsartan, irbesartan, losartan Irbesartan, losartan, candesartan
CCB preferreda
 Comparison, n 0 1
 ICER NR
 Medicines assessed Amlodipine
ACEI preferred
 Comparison, n 10 2
 ICER QALY: dominant–$17,851
LY: dominant–$13,856
NR
 Medicines assessed Lisinopril, perindopril, ramipril, benazepril, enalapril, captopril, perindopril
+indapamide
Ramipril, captopril
β-blocker preferred
 Comparison, n 1 0
 ICER QALY: dominant
 Medicines assessed Labetalol
TD preferred
 Comparison, n 10 0
 ICER QALY: $4,987–$19,945
LY: dominant–$13,856
 Medicines assessed HCTZ, indapamide, perindopril+indapamide
a
In one comparison, amlodipine is less cost-effective than conventional therapy.
ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; HCTZ, hydrochlorothiazide; 
ICER, incremental cost-effectiveness ratio; LY, life year; NR, not reported; QALY, quality-adjusted life year; TD, thiazide-type diuretic.
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Table 2C
Summary of Cost Effectiveness of Antihypertensive Medicines From the Literature Published in 1990–2016: 
Comparison Within Medicine Class (n=13).
Interventions Controls
ARBa
 Olmesartan preferred Candesartan Irbesartan Valsartan Losartan
  Comparison, n  1  2  2  2
  ICER  NR QALY: dominant QALY: dominant QALY: dominant
 Candesartan preferred Candesartan Irbesartan Valsartan Losartan
  Comparison, n  —  1  1  2
  ICER  —  NR  NR QALY: dominant
 Telmisartan preferred Candesartan Irbesartan Valsartan Losartan
  Comparison, n  0  0  1  1
  ICER  —  — QALY: $6,450–$34,678
LY: $10,275–$27,006
QALY: $4,029–14,569
LY: $2,369–$9,457
 Irbesartan preferred Candesartan Irbesartan Valsartan Losartan
  Comparison, n  0  —  2  2
  ICER  —  — QALY: dominant QALY: dominant
 Valsartan preferred Candesartan Irbesartan Valsartan Losartan
  Comparison, n  0  0  —  1
  ICER  —  —  — QALY: $31,341–$33,567
LY: $22,448–$28,326
 Losartan preferred Candesartan Irbesartan Valsartan Losartan
  Comparison, n  1  0  0  —
  ICER QALY: over threshold  —  —  —
CCB
 Nifedipine preferred Amlodipine
  Comparison, n  1
  ICER  NR
β-blocker
 Nebivolol preferred Metoprolol
  Comparison, n  1
  ICER  NR
 Celiprolol preferred Altenolol
  Comparison, n  1
  ICER BP reduction: dominant
Note: ICER for QALY and LY were summarized.
aAmong ARBs, no study used olmesartan and telmisartan as a control group.
ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CTD, 
chlorthalidone; HCTZ, hydrochlorothiazide; ICER, incremental cost-effectiveness ratio; LY, life year; NR, not reported; TD, thiazide-type diuretic; 
QALY, quality-adjusted life year.
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